Provenge, an experimental treatment vaccine for advanced prostate cancer, met researchers’ goal in a key trial needed for FDA approval.
That news comes from Dendreon, the company that makes Provenge.
“We believe this is truly a breakthrough for the prostate cancer community and a testament to the promise of the field of cancer immunotherapies,” Dendreon’s president and chief executive officer Mitchell Gold, MD, said in a conference call today.
Taiwan recorded 73,293 new cancer cases in 2006, with the largest number being colorectal cases, according to the latest cancer incidence report released yesterday by the Department of Health=.
The figures mean that on average, a new cancer patient was being diagnosed in the country every 7 minutes, 10 seconds in 2006, up slightly from the average of 7 minutes, 38 seconds in 2005, when 68,907 new cases were recorded, according to Chao Kun-yu, deputy chief of the DOH’s Bureau of Health Promotion.
The report showed that for the first time, colorectal cancer replaced liver cancer as the most common type among new cases recorded in a single year.
Nanotechnology has been used for the first time to destroy cancer cells with a highly targeted package of “tumour busting” genes.
The technique, which leaves healthy cells unaffected, could potentially offer hope to people with hard-to-treat cancers where surgery is not possible.
Although it has only been tested in mice so far, the researchers hope for human trials in two years.
The UK study is published online by the journal Cancer Research.
In seeming contradiction to previous studies where findings supported the benign or beneficial effects of alcohol consumption, a current study by researchers at the University of Oxford in Great Britain has linked even minimal alcohol use and cancer in women. The type of alcohol consumed was irrelevant.
The so-called Million Women Study of middle-aged women in the United Kingdom found that low to moderate consumption of alcohol increased the risk of and might be responsible for 13 percent of breast, liver, rectal and certain digestive tract cancers.
London, UK, and Cambridge, MA, 12 February 2009 – Antisoma plc (LSE: ASM; USOTC:ATSMY) announces that its Tumour-Vascular Disrupting Agent, ASA404, will be evaluated by Novartis as a treatment for HER2-negative metastatic breast cancer. This indication is being prioritised ahead of prostate cancer, in which a phase II trial has been completed. Details of the plans for trials in breast cancer will be available later this year.
A drug of a class commonly used to combat bone loss may reduce by a third the chance that some breast cancers will spread or recur, a large study has found.
While it may sound odd to treat cancer with a drug that acts on bone, evidence is accumulating that such drugs may do more than just prevent the loss of bone. Other studies are testing the drugs in patients with prostate or lung cancer.
While treatment for inflammatory breast cancer has improved in recent years, it still carries a worse prognosis than many other forms of breast cancer. According to the American Cancer Society, the 5-year survival rate for inflammatory breast cancer is 40 percent, compared with 87 percent for all breast cancers.
In typical breast cancers, the tumor forms a lump that a person can feel or see on a mammogram. In the inflammatory kind, which makes up 1 to 2 percent of the roughly 180,000 new breast cancer cases per year, the cancer “is often not a mass,” says Dr. Eric Winer, chief of the Division of Women’s Cancers at Dana-Farber Cancer Institute. “Instead, the breast is often warm, red, swollen and tender.” The cancer is often misdiagnosed as an infection treatable by antibiotics.
Can EVOO — extra-virgin olive oil — cut the risk of breast cancer?
Yes — but only the 20% to 30% of breast cancers that express the HER2 molecules, suggest studies by Javier A. Menendez, PhD, at the Catalan Institute of Oncology in Girona, Spain, and colleagues.
The Spanish researchers wondered why some studies show that the olive-oil-rich Mediterranean diet cuts breast cancer risk while other studies do not. They theorized that the active compounds in olive oil only affect certain cancers.
Women who underwent chest radiation therapy for a childhood cancer have a significantly higher risk for developing breast cancer at a younger age. Yet a new study in the Journal of the American Medical Association shows that many of them do not undergo the recommended screenings.
“Most young women at risk of breast cancer following chest radiation for a pediatric cancer, including women at highest risk (Hodgkin lymphoma survivors), are not being appropriately screened,” Kevin C. Oeffinger, MD, of Memorial Sloan-Kettering Cancer Center in New York, and colleagues write.
One in every hundred breast cancers or so occurs in men, and such tumors are often detected at a late stage. Furthermore, these cancers can appear benign on mammography, according to a report in the American Journal of Roentgenology.
Breast tumors in men are usually palpable by the time they’re discovered or they show signs “such as change in overlying skin or nipple,” Dr. Wei-Tse Yang told Reuters Health.
